5 independently checked trend briefs about this subject, newest first.
headlinez.news detected 5 source-qualified news clusters connected to Sanofi between June 23, 2026 and July 30, 2026. They span 2 newsroom categories and average 7.0 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Sanofi’s new CEO Garijo outlines an R&D restructuring and expansion plan as the company balances strong second-quarter earnings against investor concerns.
Sanofi has officially discontinued development of its eczema drug amlitelimab, marking a significant shift in its pipeline strategy.
The FDA has granted approval for Sanofi’s Sarclisa, marking the first time a cancer medication has been cleared for delivery via an on-body injector.
EU antitrust probe targets Sanofi’s flu vaccine campaign—what’s the scope and next move?
NHS becomes first in Europe to fund drug that can delay type 1 diabetes by years